Method of treating an ischemia-reperfusion injury-related disorder by administering gpcr ligands

Abstract

Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation.

What is claimed is: 
     
         1 . A method of treating an inflammatory and/or immune-related disorder in a subject; comprising administering to a subject in need thereof a therapeutically effective amount of the peptide selected from the group consisting of:
 i. a purified peptide comprising the amino acid sequence of anyone of SEQ ID NOs: 1-4, 26, 36-38;   ii. or a pharmaceutical composition comprising said peptide and a pharmaceutically acceptable carrier.   
     
     
         2 . The method of  claim 1 , wherein the amino acid sequence of said peptide is twenty-four or fewer amino acids in length. 
     
     
         3 . The method of  claim 1 , wherein said peptide is conjugated or fused to a second peptide or polypeptide. 
     
     
         4 . The method of  claim 1 , wherein said peptide includes a C-terminal amidated amino acid. 
     
     
         5 . The method of  claim 1 , wherein said peptide is modified at its amino terminus, and, wherein said amino terminal modification includes an N-glycated, N-alkylated, N-acetylated or N-acylated amino acid. 
     
     
         6 . The method of  claim 1 , wherein said peptide is pegylated or sialylated. 
     
     
         7 . The method of  claim 1 , wherein said peptide is encapsulated. 
     
     
         8 . The method of  claim 1 , wherein the inflammatory disorder is selected from the group consisting of gastritis, gout, gouty arthritis, arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ulcers, chronic bronchitis, asthma, allergy, acute lung injury, pulmonary inflammation, airway hyper-responsiveness, vasculitis, septic shock and inflammatory skin disorders, selected from the list comprising of psoriasis, atopic dermatitis, and eczema. 
     
     
         9 . The method of  claim 1 , wherein the inflammatory disorder is selected from the group consisting of inflammatory conditions associated with an infection, said infection being a bacterial infection or viral infection or an infection caused by another type of pathogen. 
     
     
         10 . The method of  claim 9 , wherein said inflammatory disorder is associated with a bacterial infection or viral infection or an infection caused by another type of pathogen, selected from a group consisting of a viral infection caused by human immunodeficiency virus I (HIV-1) or HIV-2, acquired immune deficiency (AIDS), West Nile encephalitis virus, coronavirus, rhinovirus, influenza virus, dengue virus, hemorrhagic fever; an otological infection; severe acute respiratory syndrome (SARS), sepsis and sinusitis. 
     
     
         11 . The method of  claim 1 , wherein the immune-related disorder is selected from the group consisting of graft versus host disease; transplant rejection, bone marrow transplantation. 
     
     
         12 . The method of  claim 1 , wherein the immune related disorder is an autoimmune disease and is selected from the group consisting of multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, transplant rejection, immune disorders associated with graft transplantation rejection, benign lymphocytic angiitis, lupus erythematosus, Hashimoto's thyroiditis, primary myxedema, Graves' disease, pernicious anemia, autoimmune atrophic gastritis, Addison's disease, insulin dependent diabetes mellitis, Good pasture's syndrome, myasthenia gravis, pemphigus, sympathetic ophthalmia, autoimmune uveitis, autoimmune hemolytic anemia, idiopathic thrombocytopenia, primary biliary cirrhosis, chronic action hepatitis, ulceratis colitis, Sjogren's syndrome, rheumatic disease, polymyositis, scleroderma, mixed connective tissue disease, inflammatory rheumatism, degenerative rheumatism, extra-articular rheumatism, collagen diseases, chronic polyarthritis, psoriasis arthropathica, ankylosing spondylitis, juvenile rheumatoid arthritis, periarthritis humeroscapularis, panarteriitis nodosa, progressive systemic scleroderma, arthritis uratica, dermatomyositis, muscular rheumatism, myositis, myogelosis and chondrocalcinosis. 
     
     
         13 . The method of  claim 1 , further comprising treating the subject with an additional therapeutic agent. 
     
     
         14 . The method of  claim 13 , wherein said peptide or said pharmaceutical composition is administered in combination with said additional therapeutic agent.